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Highlights 
• Claims on the safety of tDCS are based on inaccurate data. 
• Clinical trials fail in reporting methods applied to identify adverse effects. 
• The frequency and the adverse effects observed are also not consistently reported. 
• Appropriate methods and transparent report are needed in reviews on the safety of tDCS. 
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Dear editor: 
Last year, Bikson and colleagues attempted to collate data to inform the safety of the transcranial direct 
current stimulation (tDCS), an electrical brain stimulation technique that has been used to treat of 
neurological problems and psychiatric disorders. The review was qualified as an evidence-based review 
and the authors concluded that the review was able to “consolidate evidence on the safety of tDCS” (1). 
The study based its conclusions on the analysis of serious adverse effects and irreversible brain damage 
in animal models (1), as well as human trials published in English before 2013. The studies were 
searched in one database, PubMed, with the key word “transcranial direct current stimulation”. 
We recognise the authors attempt to aggregate evidence regarding the safety of tDCS. However, we are 
concerned about the several and important limitations in the design of this review which might 
invalidate it as an evidence-based piece. These limitations comprise both its methodological design and 
the theoretical concepts adopted. 
In regards to the methods, this safety update is inconsistent with the fundamentals of an evidence-
based review, also known as a systematic review (2). Evidence-based guidelines recommend the 
construction of highly sensitive searches to allow the retrieval of all relevant studies  (3). Sensitive 
searches should combine free-text and subject headings and they should be used to retrieve relevant 
studies indexed in different databases. Searches limited to only one database and one keyword are 
highly susceptible to publication bias. When considering adverse effects, an even more broad range of 
databases and free-text and subject headings may be searched to avoid biases (4). The language limit of 
the search to the English language might or might not be another source of bias (5, 6). Nevertheless, the 
authors should be transparent when reporting the number of retrieved studies and the results of the 
screening process (7, 8). For instance, the reader should be able to make a judgment of the size and 
direction of the bias by acknowledging the number of studies not considered for inclusion because of 
the language of the publication. 
The type of study to be included in a systematic review is another aspect of an evidence-based review to 
be taken under careful consideration. Different clinical questions require data from different study 
designs. Accurately searching for data on adverse effects may require an even more careful approach 
and the consideration of the pros and cons of including either randomised and non-randomised trials, as 
well as unpublished studies. As much as 95% of the information regarding adverse events remains 
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unpublished and information of higher complexity in regards to harms may be found in unpublished 
versions of the same published study (9). The review reported by Bikson et al. (1) neglect all these 
essential aspects of an evidence-based research focused on safety. In fact, the paper referred loosely to 
“trials” as the study design included in the review and do not mention any attempt to search for 
unpublished data. The meaning of the terminology “trials” is unclear as it may correlate with different 
types of study designs, from small short-term non-randomized studies to large, multicentre randomized 
trials with long-term evaluation of thousands of participants. Failing in approaching the unpublished 
literature seriously threatens the validity of the review results. 
Another critical aspect is related to the assessment of the risk of bias toward the null hypothesis of no 
effect. What was measured, who measured it, and when it was measured may define if an adverse 
effect can, or will, be appropriately detected or not. Lack of proper or rigorous measurement methods 
to detect adverse effects does not mean safety as even serious events could have been missed. 
Similarly, outcome reporting bias, or the neglecting in reporting an outcome, can seriously influence the 
results of any review focusing on harmful outcomes (10). Studies may fail to provide full and transparent 
reporting of adverse effects and the fact that they are not reported does not mean they didn’t happen. 
For instance, our group performed a systematic review of randomised clinical trials of tDCS in stroke 
survivors and the results demonstrated that the majority of the trials suffer from poor reporting. 
Information on the methods applied to collect data on adverse effects, the frequency and the specific 
adverse effects observed is largely not transparently reported (Table 1). Our results are consistent with 
another review showing that 40.7% of the studies assessing treatment with tDCS in stroke patients fail 
to mention whether adverse effects were measured or not and whether they occurred or not (11). 
Therefore, the conclusion that there are no reports of serious adverse effects associated to tDCS could 
better represent an “absence of evidence of harms” rather than “evidence of absence of harms” (12). 
The concept of safety applied in this review is another matter of concern. Safety is the “substantive 
evidence of an absence of harm” (13). Evidence of safety should then be understood as evidence of the 
absence of the totality of all possible adverse consequences of an intervention or, alternatively, 
evidence that the beneficial effects of an intervention outweigh its possible adverse consequences. The 
authors of the quoted evidence-based review opted to evaluate safety based only on serious adverse 
effects with published data allowing the assessment of causality. There are two misconceptions here. 
Firstly, by definition, an adverse effect is an event for which there is a reasonable possibility of a causal 
relation (13). Therefore, a definitive prove of causality is not necessary and, in fact, may not be reached 
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in the majority of the cases. Secondly, mild or moderate adverse effects may significantly reduce 
patient’s quality of life and their willingness in adhering to treatment. Therefore, safety should not be 
related only to serious events, and the ultimate decision on which an adverse effect is tolerable or not 
should rely on the patient. 
High quality research should provide evidence for an improved informed and shared clinical decision. 
Unfortunately, the terminology evidence-based has become popular. This may be dangerous as flawed 
research may claim to provide definitive clinical answers without an appropriate appraisal of the quality 
and accuracy of the data. We regret to conclude that, ultimately, declaring tDCS a safe technique in face 
of the limitations of the published review could do more harm than good to patients undergoing 
treatment.  
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Table 1 Reporting of data related to adverse effects in randomised controlled trials of treatment of stroke patients with transcranial direct 
current stimulation (tDCS) - data are from a systematic review with searches at The Cochrane Central Register of Controlled Trials (CENTRAL), 
PEDRo and Biosis Preview databases updated until November 2014. 
Author, year of publication
a
 Assessment methods of adverse effects 
Data on frequency of adverse 
events? 
Nº of tables/graphs 
describing adverse effects 
Bologini 2011 Questionnaire administered at end of each session tDCS No 0 
Danzl 2013 NR No 0 
Edwards 2009 NR No 0 
Gandinga 2006 
Visual analogical scale applied in each session and ranging 
from 1 (no discomfort) to 10 (extreme discomfort/pain) 
No 0 
Geroin 2011 NR No 0 
Khedr 2013 NR No 0 
Kim 2010 NR No 0 
Kumar 2011 NR No 0 
Lee 2014 NR No 0 
Lindenberg 2010 NR No 0 
Nair 2011 NR No 0 
Polanowska  2013 NR No 1 
Rossi 2013 NR No 0 
Viana 2014 NR No 0 
Wu 2013 NR No 0 
Yang 2012 NR No 0 
You 2011 NR No 0 
Ang 2012 No No 0 
Fusco 2014 NR No 0 
Park 2013 NR No 0 
Polanowska 2013 NR No 0 
Shigematsu 2013 NR No 0 
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Wilkinson 2014 
Charts with daily record of adverse effects taken before 
and during the sessions 
Yes 1 
NR: not reported. 
a
 The detailed list of references can be obtained through contacting authors. 
